Corteria Pharmaceuticals: Funding, Investors & Team (Sep 2026)
Corteria Pharmaceuticals specializes in creating novel medications targeting specific groups of heart failure patients, with a strong emphasis on developing groundbreaking treatments for worsening and sudden-onset heart failure.
Corteria Pharmaceuticals has raised $69.5M across 1 funding round on record, the most recent a Series A of $69.5M announced in Sep 2023.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Corteria Pharmaceuticals Company Profile and Key Stats
Latest funding round on record: Sep 2023.
Corteria Pharmaceuticals Funding Rounds
Corteria Pharmaceuticals Founders and Leadership Team
Contact details for the Corteria Pharmaceuticals team: 1 of 1 has an email address on file.
Start 14-day free trial →Corteria Pharmaceuticals Funding Compared to Other Biotechnology Startups
Corteria Pharmaceuticals' latest round of $69.5M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Corteria Pharmaceuticals in Biotechnology and Paris
Companies Similar to Corteria Pharmaceuticals
Brenus Pharma is a platform that uses allogeneic techniques to create immune therapy with the goal of…
TISSIUM is a privately owned medical device company based in Paris, France that is dedicated to the rapid…
NicOx is a biopharmaceutical company that focuses on creating and selling nitric oxide-donating drugs for…
Advicenne is a specialty pharmaceutical company dedicated to improving the lives of patients who suffer from…
One Biosciences was founded in Paris, Ile-de-France, France by Magali Richard, David Schilansky, and Céline…
Inventiva Pharma is a biopharmaceutical company in the clinical stage that focuses on creating oral small…
NETRIS Pharma develops therapeutic molecules for treating cancer by targeting dependence receptors for the…
AbIONYX Pharma is a biotechnology company that is focused on providing innovative therapies for indications…
Founded in 2003, Nanobiotix is at the forefront of nanomedicine and is committed to revolutionizing patient…
Theraclion specializes in high-tech medical equipment using high-intensity focused ultrasound (HIFU). They…
Abivax, a clinical stage biotechnology company, is mobilizing the body’s natural immune machinery to treat…
AB Science was established in 2001 by a group of individuals in the medical and business fields who are…
Corteria Pharmaceuticals Funding FAQs
What does Corteria Pharmaceuticals do?
Corteria Pharmaceuticals specializes in creating novel medications targeting specific groups of heart failure patients, with a strong emphasis on developing groundbreaking treatments for worsening and sudden-onset heart failure.
How much funding has Corteria Pharmaceuticals raised?
Corteria Pharmaceuticals has raised $69.5M across 1 round on record. The most recent is a Series A of $69.5M announced in Sep 2023.
When did Corteria Pharmaceuticals last raise funding?
Corteria Pharmaceuticals' most recent funding round on record is a Series A of $69.5M, announced in Sep 2023.
Who is the CEO of Corteria Pharmaceuticals?
Philip Janiak is listed as CEO at Corteria Pharmaceuticals.
Where is Corteria Pharmaceuticals headquartered?
Corteria Pharmaceuticals is based in Paris, Ile-De-France, France.
How many employees does Corteria Pharmaceuticals have?
Corteria Pharmaceuticals is in the 1-10 employee band.
How does Corteria Pharmaceuticals' funding compare to other Biotechnology startups?
Corteria Pharmaceuticals' latest round of $69.5M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.
About FundedIQ's Corteria Pharmaceuticals Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Corteria Pharmaceuticals is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.